{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for pantothenic root_modifications_structuralModifications_molecularFragment_refPname in root_modifications_structuralModifications_molecularFragment_refPname (approximate match)
Status:
Possibly Marketed Outside US
Source:
Sotrovimab by GlaxoSmithKline LLC
(2021)
Source URL:
First approved in 2021
Source:
Sotrovimab by GlaxoSmithKline LLC
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
Bamlanivimab by Eli Lilly and Company
(2020)
Source URL:
First approved in 2020
Source:
Bamlanivimab by Eli Lilly and Company
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
Imdevimab by Regeneron Pharmaceuticals, Inc.
(2020)
Source URL:
First approved in 2020
Source:
Imdevimab by Regeneron Pharmaceuticals, Inc.
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
Casirivimab by Regeneron Pharmaceuticals, Inc.
(2020)
Source URL:
First approved in 2020
Source:
Casirivimab by Regeneron Pharmaceuticals, Inc.
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
BLA761158
(2020)
Source URL:
First approved in 2020
Source:
BLA761158
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 352
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
First approved in 2016
Source:
BLA125582
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
First approved in 2015
Source:
BLA125426
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
Alprolix by Bioverativ Canada Inc [Canada]
Source URL:
First approved in 2014
Source:
BLA125444
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
Octaplex by Octapharma Pharmazeutika Produktionsges M B H [Canada]
Source URL:
First approved in 2013
Source:
BLA125421
Source URL:
Class:
PROTEIN
